My Health Tags - To improve taking tablets for heart failure
- Conditions
- Specialty: Cardiovascular disease, Primary sub-specialty: Heart failureUKCRC code/ Disease: Cardiovascular/ Hypertensive diseasesCirculatory SystemHeart failure
- Registration Number
- ISRCTN58513123
- Lead Sponsor
- niversity Hospitals Bristol NHS Foundation Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 30
1. Age over 18 years
2. Able to provide informed consent
3. Diagnosis of heart failure made more than one month prior to enrollment
4. On medication for heart failure including ACEi/ARB and B-blocker
5. Has 4 week supply of ACE/ARB and B blocker
6. Live in postcode areas BS1 – BS16
7. Able to read and understand instructions in English
1. Medication given by partner or other care-provider
2. Use of dosette box
3. History of advanced dementia
4. Planned travel away for home for more than 7 consecutive days during the study period
5. 3G and WiFi signal absent or very poor in patient’s home
6. Expected to change dose of ACEi/ARB or BB during the study period
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of ACE/ARB and Beta Blocker heart failure tablets taken during the study period, calculated from the pill count taken by the research nurse at baseline, 4, and 8 weeks
- Secondary Outcome Measures
Name Time Method <br> 1. Mean difference between groups, in the proportion of patients with chronic heart failure taking >80% of prescribed pills (ACEi/ARB and BB) over a four-week period<br> 2. Mean difference between groups in change in MMAS-8 scores measured at baseline, 4, and 8 weeks between baseline and the end of the treatment block<br> 3. Mean difference between groups in change in urine metabolite numbers, measured at baseline, 2, 4, 6 and 8 weeks between baseline and the end of the treatment block<br>